Slope initially began as a blog, so this is where most of the website’s content resides. Here we have tens of thousands of posts dating back over a decade. These are listed in reverse chronological order. Click on any category icon below to see posts tagged with that particular subject, or click on a word in the category cloud on the right side of the screen for more specific choices.
Eli Lilly has traditionally scared me. I mean, let’s face it, a totally evil company that sells drugs at 10,000 the times of the cost of materials which has the pathetic U.S. healthcare system over a barrel is a pretty damned good business model. It is sporting a P/E in the triple digits, which is normally what you would associate with a new biotech company at the cusp of curing cancer, not an ancient organization that sells stupidly named pills to the desperate.
Good morning, everyone, and welcome to the second half of our shortened trading week. As a reminder, the three-legged investment outlook I have is simple: bullish gold, bullish bonds, bearish equities. This week, it is playing out nicely!
I just noticed that, a few days ago, I did my 39,000th post! The market has been too fun lately for me to notice. Oh, well. There’s always 40,000 as a milestone. Let’s look at some indexes. I’m afraid it’s a bit of a mixed bag of maybe this, maybe that.
The NASDAQ Composite has been crumbling at various speeds for many days in a row, but it may be approaching a modest level of support by way of the price gap (horizontal dashed green line). Slicing through this would open up the door for challenging the August 5th lows sometime this month. Wouldn’t that be something?
